Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Active not recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Triple Negative Breast Neoplasms 2Breast Neoplasms 2Smoldering Multiple Myeloma 1Neoplasms, Plasma Cell 1

Interventions

Paclitaxel 62Letrozole 55Fulvestrant 55Trastuzumab 50palbociclib 41pembrolizumab 37Cyclophosphamide 37Carboplatin 37Anastrozole 37pertuzumab 35exemestane 25Tamoxifen 24Capecitabine 24ribociclib 23abemaciclib 23Radiotherapy 21Docetaxel 21olaparib 20Doxorubicin 20Magnetic Resonance Spectroscopy 19trastuzumab deruxtecan 17Surveys and Questionnaires 17durvalumab 16Epirubicin 16Specimen Handling 14Exercise 14130-nm albumin-bound paclitaxel 14Taxes 13Alpelisib 13Goserelin 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Breast Neoplasms × PVX-410 vaccine × Clear all
NCT02826434 2025-10-01

Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer

Massachusetts General Hospital

Phase 1 Active not recruiting
22 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03362060 2025-10-01

PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer

Massachusetts General Hospital

Phase 1 Active not recruiting
20 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡